

Table 14-3.12
Mean NPI-X Total Score from Week 4 through Week 24 - Windowed

	Placebo (N=79)	Xanomeline Low Dose (N=81)	Xanomeline High Dose (N=74)
Baseline			
n	79	81	74
Mean (SD)	9.5 (12.10)	8.7 (9.82)	11.9 (13.70)
Median (Range)	5.0 (0;66)	4.0 (0;32)	8.0 (0;61)
Mean of Weeks 4-24			
n	78	75	69
Mean (SD)	9.3 (11.18)	9.1 (12.10)	9.6 (11.60)
Median (Range)	5.5 (0;65)	3.8 (0;51)	4.4 (0;46)
p-value(Dose Response) [1][2]			0.637
p-value(Xan - Placebo) [1][3]		0.760	0.517
Diff of LS Means (SE)		0.3 (1.13)	-0.7 (1.15)
95% CI		(-1.9;2.6)	(-3.0;1.5)
p-value(Xan High - Xan Low) [1][3]			0.350
Diff of LS Means (SE)			-1.1 (1.17)
95% CI			(-3.4;1.2)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006